Kyowa Kirin Co., Ltd.
4151.TDrugs in Pipeline
59
Phase 3 Programs
32
Upcoming Catalysts
2
Next Catalyst
Aug 31, 2026
19wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ARQ197
Liver Cancer
KHK4827 140mg SC
Psoriasis Vulgaris
OPC-262
Type 2 Diabetes
Antithrombin gamma
Preeclampsia
KHK7791
Hyperphosphatemia
KRN23
X-linked Hypophosphatemia
Istradefylline 20 mg or 40 mg
Idiopathic Parkinson's Disease
AMG 531
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
OPC-262 2.5 mg
Diabetes Type 2
darbepoetin alfa
Anemia
KW-6500
Parkinson's Disease
KW-2246
Cancer Related Pain (Breakthrough Pain)
Istradefylline
Parkinson's Disease
KW-2246 (fentanyl citrate)
Pain, Cancer
KHK7580
Secondary Hyperparathyroidism
EN3267
Pain
KW-3357
Disseminated Intravascular Coagulation (DIC)
Istradefylline 40 mg
Idiopathic Parkinson's Disease
saxaglipitin
Diabetes
Granisetron
Chemotherapy-induced Nausea and Vomiting
KK8398
Achondroplasia
Romiplostim
Aplastic Anemia
Cinacalcet Hydrochloride
Secondary Hyperparathyroidism
Brodalumab
Axial Spondyloarthritis
Istradefylline ( KW-6002)
Parkinson's Disease
Humira®
Arthritis, Rheumatoid
FKB327
Arthritis, Rheumatoid
burosumab
X-linked Hypophosphatemia
Cinacalcet HCl
Parathyroid Carcinoma
KRN1493
Secondary Hyperparathyroidism
Istradefylline (KW-6002)
Parkinson's Disease
KHK4827
Moderate to Severe Systemic Sclerosis
KHK6188
Postherpetic Neuralgia
KHK4083
Ulcerative Colitis
RTA 402
Chronic Kidney Disease
Entinostat
Advanced or Recurrent Breast Cancer
apomorphine hydrochloride
Parkinson's Disease
KHK4951
Neovascular Age-Related Macular Degeneration (nAMD)
KRN125(pegfilgrastim), PLR001(plerixafor)
Multiple Myeloma and Malignant Lymphoma
VCAP/AMP/VECP(mLSG15)
Adult T-cell Leukemia-Lymphoma
KW-0761
Peripheral T/NK-cell Lymphoma
Pralatrexate
Adult T-cell Leukemia-Lymphoma
benralizumab
Eosinophilic Chronic Rhinosinusitis
Aflibercept Injection
Diabetic Macular Edema (DME)
KHK7580 low dose
Secondary Hyperparathyroidism
KHK4577
Atopic Dermatitis
KW-0761 (mogamulizumab)
Peripheral T-Cell Lymphoma
ME-401
Indolent B-cell Non-Hodgkin's Lymphoma
KW-6356
Parkinson's Disease
KHK4563
Uncontrolled and Suspected Eosinophilic Asthma
AMG531
Aplastic Anemia
pegfilgrastim
Neutropenia
KW-2478
Multiple Myeloma
Romiplostim (AMG-531)
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
KK8123
X-linked Hypophosphatemia
ARQ 197
Gastric Cancer
KRN321
MDS
Placebp
Hyperphosphatemia
saxagliptin
Diabetes, Type 2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ARQ197 | Phase 3 | Liver Cancer | - | - |
KHK4827 140mg SC | Phase 3 | Psoriasis Vulgaris | - | - |
OPC-262 | Phase 3 | Type 2 Diabetes | - | - |
Antithrombin gamma | Phase 3 | Preeclampsia | - | - |
KHK7791 | Phase 3 | Hyperphosphatemia | - | - |
KRN23 | Phase 3 | X-linked Hypophosphatemia | - | - |
Istradefylline 20 mg or 40 mg | Phase 3 | Idiopathic Parkinson's Disease | - | - |
AMG 531 | Phase 3 | Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | - | - |
OPC-262 2.5 mg | Phase 3 | Diabetes Type 2 | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
KW-6500 | Phase 3 | Parkinson's Disease | - | - |
KW-2246 | Phase 3 | Cancer Related Pain (Breakthrough Pain) | - | - |
Istradefylline | Phase 3 | Parkinson's Disease | - | - |
KW-2246 (fentanyl citrate) | Phase 3 | Pain, Cancer | - | - |
KHK7580 | Phase 3 | Secondary Hyperparathyroidism | - | - |
EN3267 | Phase 3 | Pain | - | - |
KW-3357 | Phase 3 | Disseminated Intravascular Coagulation (DIC) | - | - |
Istradefylline 40 mg | Phase 3 | Idiopathic Parkinson's Disease | - | - |
saxaglipitin | Phase 3 | Diabetes | - | - |
Granisetron | Phase 3 | Chemotherapy-induced Nausea and Vomiting | - | - |
KK8398 | Phase 3 | Achondroplasia | - | - |
Romiplostim | Phase 3 | Aplastic Anemia | - | - |
Cinacalcet Hydrochloride | Phase 3 | Secondary Hyperparathyroidism | - | - |
Brodalumab | Phase 3 | Axial Spondyloarthritis | - | - |
Istradefylline ( KW-6002) | Phase 3 | Parkinson's Disease | - | - |
Humira® | Phase 3 | Arthritis, Rheumatoid | - | - |
FKB327 | Phase 3 | Arthritis, Rheumatoid | - | - |
burosumab | Phase 3 | X-linked Hypophosphatemia | - | - |
Cinacalcet HCl | Phase 3 | Parathyroid Carcinoma | - | - |
KRN1493 | Phase 3 | Secondary Hyperparathyroidism | - | - |
Istradefylline (KW-6002) | Phase 3 | Parkinson's Disease | - | - |
KHK4827 | Phase 3 | Moderate to Severe Systemic Sclerosis | - | - |
KHK6188 | Phase 2 | Postherpetic Neuralgia | - | - |
KHK4083 | Phase 2 | Ulcerative Colitis | - | - |
RTA 402 | Phase 2 | Chronic Kidney Disease | - | - |
Entinostat | Phase 2 | Advanced or Recurrent Breast Cancer | - | - |
apomorphine hydrochloride | Phase 2 | Parkinson's Disease | - | - |
KHK4951 | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
KRN125(pegfilgrastim), PLR001(plerixafor) | Phase 2 | Multiple Myeloma and Malignant Lymphoma | - | - |
VCAP/AMP/VECP(mLSG15) | Phase 2 | Adult T-cell Leukemia-Lymphoma | - | - |
KW-0761 | Phase 2 | Peripheral T/NK-cell Lymphoma | - | - |
Pralatrexate | Phase 2 | Adult T-cell Leukemia-Lymphoma | - | - |
benralizumab | Phase 2 | Eosinophilic Chronic Rhinosinusitis | - | - |
Aflibercept Injection | Phase 2 | Diabetic Macular Edema (DME) | - | - |
KHK7580 low dose | Phase 2 | Secondary Hyperparathyroidism | - | - |
KHK4577 | Phase 2 | Atopic Dermatitis | - | - |
KW-0761 (mogamulizumab) | Phase 2 | Peripheral T-Cell Lymphoma | - | - |
ME-401 | Phase 2 | Indolent B-cell Non-Hodgkin's Lymphoma | - | - |
KW-6356 | Phase 2 | Parkinson's Disease | - | - |
KHK4563 | Phase 2 | Uncontrolled and Suspected Eosinophilic Asthma | - | - |
AMG531 | Phase 2 | Aplastic Anemia | - | - |
pegfilgrastim | Phase 2 | Neutropenia | - | - |
KW-2478 | Phase 2 | Multiple Myeloma | - | - |
Romiplostim (AMG-531) | Phase 2 | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | - | - |
KK8123 | Phase 2 | X-linked Hypophosphatemia | - | - |
ARQ 197 | Phase 2 | Gastric Cancer | - | - |
KRN321 | Phase 2 | MDS | - | - |
Placebp | Phase 2 | Hyperphosphatemia | - | - |
saxagliptin | Phase 2 | Diabetes, Type 2 | - | - |
Postherpetic Neuralgia
1 drug in this indication
Ulcerative Colitis
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Advanced or Recurrent Breast Cancer
1 drug in this indication
Secondary Hyperparathyroidism
1 drug in this indication
Parathyroid Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)